Functional Recovery in Aged and Young Rats After Embolic Stroke
Treatment With a Phosphodiesterase Type 5 Inhibitor

Li Zhang, MD; Rui Lan Zhang, MD; Ying Wang, MD; Chunling Zhang, BS; Zheng Gang Zhang, MD, PhD; He Meng, MD, PhD; Michael Chopp, PhD

Background and Purpose—Advanced age is associated with a decrease in brain plasticity compared with the young adult. Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor promotes brain plasticity and improves functional outcome after stroke in the young animal. Here, we test the hypothesis that sildenafil provides restorative therapeutic benefit to the aged animal.

Methods—Male Wistar rats (aged, 18-month old; young, 3-month old) were subjected to embolic stroke. Saline or sildenafil was administered daily at a dose of 2 mg/kg orally or 10 mg/kg subcutaneously for 7 consecutive days starting 24 hour after stroke onset.

Results—Aged rats exhibited significant impairment of functional recovery and reductions of vascular density, and endothelial cell proliferation compared with young rats. Aged rats treated with sildenafil at a dose of 10 mg/kg but not 2 mg/kg, showed significant improvements of functional recovery and concomitant increases in cortical cyclic guanosine 3',5'-cyclic monophosphate (cGMP) level, vascular density, endothelial cell proliferation, and synaptogenesis compared with aged rats treated with saline. In young rats, treatment with sildenafil at a dose of 2 or 10 mg/kg significantly enhanced functional recovery and amplified brain plasticity compared with young rats treated with saline.

Conclusion—Age is associated with reduction of angiogenesis, and poor neurological functional recovery after stroke. However, treatment of aged stroke rats with sildenafil improves functional recovery that is likely fostered by enhancement of angiogenesis and synaptogenesis. (Stroke. 2005;36:847-852.)

Key Words: angiogenesis ■ embolism ■ recovery of function

Phosphodiesterase type 5 (PDE 5) enzyme is highly specific for hydrolysis of cGMP and regulates cGMP signaling.1,2 Administration of an NO donor elevates cerebral cGMP level, and improves neurological functional recovery in young rats after stroke.3 In normal rats, administration of sildenafil, an inhibitor of PDE 5 elevates cortical cGMP level.4 Treatment of stroke with sildenafil improves neurological functional recovery in young rats.4

Aged rats exhibit a decrease in the basal brain levels of cGMP which may have important functional implications such as, for learning and memory.5 Thus, the efficacy of sildenafil treatment of stroke in the aged animal may significantly decline with aging, which may have important clinical implications for stroke treatment because stroke is a major cause of death and disability in the elderly.6 Accordingly, in the present study, we test the hypothesis that treatment of stroke with sildenafil improves neurological functional recovery in aged rats after stroke.

Materials and Methods
Male Wistar rats at ages of 8 to 12 weeks (Charles River Breeding Co, Wilmington, Mass) and 18 months (Harlan Winkelmann GMBH, Germany) were classified as young and aged, respectively. Rats were individually housed in standard Plexiglas laboratory cages (550×350×260 mm) within a large well-ventilated room with a constant temperature of 23°C with a 12-hour light/dark cycle, and free access to food and water. Sildenafil (Viagra, Pfizer Inc) is a weak basic compound, which has a half-life of 0.4 hour in male rats.7

Animal Model
The MCA was occluded by placement of an embolus at the origin of the MCA, as previously described.8 All experimental procedures were approved by the Institutional Animal Care and Use Committee.

Experimental Protocol
To examine the effect of sildenafil on aged rats, sildenafil was administered at a dose of 2 mg/kg (n=10) orally (PO) or 10 mg/kg (n=8) subcutaneously (SQ) to rats 24 hours after MCA occlusion and daily for an additional 6 days. Aged stroke rats (n=15) were treated with the same volume of saline as the control group. To

Received September 17, 2004; final revision received December 16, 2004; accepted January 14, 2005.
From the Department of Neurology (L.Z., R.L.Z., Y.W., C.Z., Z.Z., H.M., M.C.), Henry Ford Health Sciences Center, Detroit, Mich; and the Department of Physics (M.C.), Oakland University, Rochester, Mich.
Correspondence to Michael Chopp, PhD, Henry Ford Hospital, Department of Neurology, 2799 West Grand Boulevard, Detroit, MI 48202. E-mail chopp@neuro.hfh.edu
© 2005 American Heart Association, Inc.

Stroke is available at http://www.strokeaha.org DOI: 10.1161/01.STR.0000158923.19956.73

847
TABLE 1. Mortality Rate and Infarct Volume

<table>
<thead>
<tr>
<th></th>
<th>Mortality Rate, %</th>
<th>Infarct Volume (% of Hemisphere)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Young</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>9</td>
<td>38.8±12.2</td>
</tr>
<tr>
<td>Sildenafil, 2 mg/kg</td>
<td>10</td>
<td>38.1±10.5</td>
</tr>
<tr>
<td>Sildenafil, 10 mg/kg</td>
<td>8</td>
<td>36.9±2.2</td>
</tr>
<tr>
<td><strong>Aged</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>47*</td>
<td>32.8±14.8</td>
</tr>
<tr>
<td>Sildenafil, 2 mg/kg</td>
<td>30</td>
<td>33.1±9.3</td>
</tr>
<tr>
<td>Sildenafil, 10 mg/kg</td>
<td>13</td>
<td>30±9.2</td>
</tr>
</tbody>
</table>

Values are mean±SE.

*P<0.05 vs respective young groups.

TABLE 2. Neurological Functional Tests

<table>
<thead>
<tr>
<th></th>
<th>NSS (Scores)</th>
<th>Adhesive Removal Test (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 d</td>
<td>7 d</td>
</tr>
<tr>
<td></td>
<td>1 d</td>
<td>7 d</td>
</tr>
<tr>
<td><strong>Young</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>10±0.3</td>
<td>8.3±0.3</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>10±0.2</td>
<td>7.7±0.4</td>
</tr>
<tr>
<td>10 mg/kg</td>
<td>11±0.4</td>
<td>7.0±0.3*</td>
</tr>
<tr>
<td><strong>Aged</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>11.5±0.5†</td>
<td>8.8±0.5</td>
</tr>
<tr>
<td>2 mg/kg</td>
<td>11.3±0.5</td>
<td>8.1±0.4</td>
</tr>
<tr>
<td>10 mg/kg</td>
<td>11±0.6</td>
<td>7.4±0.4</td>
</tr>
</tbody>
</table>

Values are mean±SE.

*P<0.05 vs respective saline treated groups.
†P<0.05 vs saline treated young rats.

Foot-Fault Test

Rats were tested for placement dysfunctions of forelimbs with the modified foot-fault test.11 The total number of steps (movement of each forelimb) that the rat used to cross the grid and the total numbers of foot faults for each forelimb were recorded.

Corner Test

Rats were tested for vibrissae sensory, postural, and motor asymmetries with the corner test.12 The number of ipsilateral (right) turns was recorded from 10 trials for each test.

Histopathologic Studies

At 30 days after MCA occlusion, each rat was transcardially perfused with heparinized saline followed by 4% paraformaldehyde. Brains were removed and fixed in 4% paraformaldehyde. Infarct volume was measured on 7 hematoxylin and eosin (H&E) stained coronal sections using a Global Laboratory Image analysis program (Data Translation), as previously described.8

Immunohistochemistry and Quantification

For morphological analysis of vessels, a monoclonal antibody (mAb) against WVF (DAKO, Glostrup, Denmark) was used at a titer of 1:400. For measurement of cerebral vascular density, 2 vWF immunostained coronal sections (6 um) at bregma -0.2, and -2.8 mm were digitized using a 20x objective via the Microcomputer Imaging Device system. The numbers of vessels were counted throughout the ischemic boundary area. The total number of vessels was divided by the total boundary area to determine vascular density.

For BrdU immunostaining, a mAb against BrdU (Boehringer Mannheim) was used at a titer of 1:1000. To quantify BrdU immunoreactive endothelial cells, numbers of endothelial cells and numbers of BrdU immunoreactive endothelial cells in 10 enlarged vessels adjacent to the ischemic lesion and 10 vessels of the contralateral homologous area were counted from each rat. Data are presented as a percentage of BrdU immunoreactive endothelial cells to total endothelial cells in 10 enlarged vessels from each rat.

To detect presynaptic plasticity and synaptogenesis, a mAb (antisyntrophin) (Boehringer Mannheim) was used at a titer of 1:500.13 For quantification of syntrophin immunoreactivity, 2 immunostained coronal sections (bregma -0.2, -2.8 mm) and 8 fields of view from the ischemic boundary area and the contralateral homologous area in each section were digitized under a 20x objective. The syntrophin immunoreactive area was measured. Data are presented as a percentage compared with the contralateral homologous region on the same section.

cGMP Measurement in Brain Tissue

Male Wistar rats at ages of 8 to 12 weeks (n=8) and 15 months (n=4; Charles River Breeding Co. Wilmington, Mass) were used to examine the effects of age and sildenafil on brain cGMP levels at 7
days after stroke, respectively. The ipsilateral hemisphere cortical tissue was rapidly removed and dissected. Levels of cGMP were measured with the use of a commercially available low-pH immunnoassay kit (R&D Systems Inc) according to the manufacturer’s instruction.

Statistics
Two-way analysis of variance (ANOVA) was used to test overall treatment and age effects of ordinal data between groups. Logistic regression analysis was used to test the mortality rate among the groups. All values are presented as mean ± SE. Statistical significance was set at P<0.05.

Results

Mortality
A significant increase of mortality rate (P<0.05) was detected in aged rats compared with young rats after saline treatment (Table 1). Rats died between 2 and 24 days after stroke onset. No animals died during or immediately after induction of cerebral ischemia, or immediately after drug administration. Rats that died were excluded from further evaluation.

Lesion Volume
There was no significant difference of infarct volume among the groups (Table 1).

Neurological Functional Outcome
After saline treatment, aged rats exhibited a significantly greater impairment of neurological function measured by NSS at 1 day, and by the adhesive removal test at 14, 21, and 30 days after stroke compared with young rats. However, no significant difference of the foot-fault test score and corner test score was detected among saline treated aged and young rats after stroke (Table 2). In aged rats, treatment with sildenafil at a dose of 10 mg/kg SQ significantly (P<0.05) increased the percentage of synaptophysin immunoreactive area in aged rats compared with their respective saline treated rats. (Figure 1).

Effects of Sildenafil on Synaptophysin
After stroke, no significant difference of the synaptophysin immunoreactivity was detected among saline treated aged and young rats. Treatment with sildenafil at a dose of 10 mg/kg SQ significantly (P<0.05) increased the percentage of synaptophysin immunoreactive area in aged and young rats compared with their respective controls (Figure 2).

Discussion
The present study demonstrates that aged rats exhibited impairment of functional recovery and angiogenesis after
embolic stroke and that treatment with sildenafil improves functional recovery that was associated with enhancement of angiogenesis and synaptogenesis around the ischemic boundary regions. Thus, aged brain has the capacity to enhance plasticity in response to sildenafil treatment.

Although histological analysis showed that infarct volume in the aged rat is comparable with the data obtained from the young rats, a significantly higher mortality rate and more severe neurological functional impairments, ie, adhesive removal test and NSS, were detected in aged versus young rats. Our data are in good agreement with clinical findings and previous experimental studies.6,14,15,16 Thus, our data demonstrate that aging is an important determinant of outcome after embolic stroke. The different patterns of age associated functional outcome measured by NSS and the adhesive removal test suggests that these outcome measurements target different aspects of functional outcome after ischemia. Adhesive removal test measures somatosensory dysfunction, whereas NSS measures an amalgamation of motor, sensory, reflex, and balance outcome.9,10 Adhesive removal times in saline treated aged rats were significantly higher than in young rats during 14 to 30 days after stroke, whereas a significant difference on NSS was only detected at day 1 after stroke, suggesting that the adhesive removal test is a more sensitive indicator of aged related functional impairments after stroke. The lack of significant differences of functional outcome between aged and young rats measured by foot-fault test and corner test suggests that these two tests are not sufficiently sensitive to assess age related functional deficits after stroke.
Aging is associated with reduced expression of vascular endothelial growth factor (VEGF) and impairment of angiogenesis, which may result in poor functional recovery after stroke. The restoration of cerebral circulation after angiogenesis is important in the ischemic brain for functional recovery after a stroke. In the central nervous system, NO/cGMP signaling promotes angiogenesis, neurogenesis, axonal outgrowth, and synaptic plasticity during development and in the adult animal. However, advanced age is associated with impairment of NO/cGMP pathway, which may result in poor brain plasticity. In the experimental model of stroke, administration of sildenafil and an NO donor, DETANONOate, increases brain levels of VEGF and angiogenesis in the ischemic brain, suggesting that cGMP contributes to NO-induced VEGF synthesis. Specific cGMP-dependent protein kinase type I knockout mice exhibit strongly reduced cerebellar long-term depression of synaptic transmission, which suggest that cGMP is involved in cerebellar synaptic plasticity. In the present study, cortical cGMP level and angiogenesis are significantly reduced in aged rats compared with young rats after stroke. Our data suggest that the impairment of functional recovery in aged rats after stroke are presumably because of the reduction of angiogenesis as a consequence of age-related reduction of cGMP production.

In the present study, treatment with sildenafil at a dose of 10 mg/kg SQ increased angiogenesis, synaptogenesis, and improved neurological functional recovery in both young and aged rats. However, treatment with sildenafil at a dose of 2 mg/kg PO significantly improved functional recovery in young rats, but failed to show improvement in aged rats. Plasma concentrations of sildenafil were above the levels associated with therapeutic efficacy in humans (5 to 15 ng/mL) for at least 1 hour after dosing with 10 mg/kg SQ in young rats, but below these levels after 2 mg/kg PO even though neurological function was also improved by this dose of sildenafil. Although plasma concentrations were not measured in aged rats, sildenafil concentrations were likely to have been higher in the aged rats (unpublished data, Pfizer Global Research and Development) suggesting that pharmacokinetic differences were not responsible for the lack of effect at 2 mg/kg PO. Moreover, administration of sildenafil at a dose of 10 mg/kg SQ resulted in a 30% increase of cortical cGMP levels in aged rats at 7 days after stroke, whereas a 60% increase was detected in young rats. Collectively, our data suggest that although limited, the aged brain retains the capacity to increase cGMP level in response to sildenafil treatment, and to subsequently enhance angiogenesis and synaptic plasticity. The failure of functional improvement after low-dose sildenafil treatment (2 mg/kg, PO) in aged animal is likely attributed to the impaired endogenous brain plasticity in the aged versus young rats (see Figure 1, 2).

In summary, present study demonstrates that age is associated with impairment of angiogenesis after stroke. Treatment with sildenafil improves neurological functional, and enhances brain plasticity in young and aged rats after MCA occlusion.

Acknowledgments
This work was supported by National Institute of Neurological Disorders and Stroke grants PO1 NS23393, PO1 NS42345, RO1 HL64766, and RO1 NS38292. We thank Cynthia Roberts, and Qing-e Lu for technical assistance.

References
Functional Recovery in Aged and Young Rats After Embolic Stroke: Treatment With a Phosphodiesterase Type 5 Inhibitor
Li Zhang, Rui Lan Zhang, Ying Wang, Chunling Zhang, Zheng Gang Zhang, He Meng and Michael Chopp

Stroke. 2005;36:847-852; originally published online March 3, 2005;
doi: 10.1161/01.STR.0000158923.19956.73
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/36/4/847

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/